The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases

Neoplasia

Volumn 11, Issue 5, 2009, Pages 448-458

  Pillay, Vinochani ^a   Allaf, Layal ^a,b   Wilding, Alexander L ^a,b   Donoghue, Jacqui F ^b   Court, Naomi W ^b   Greenall, Steve A ^a,b   Scott, Andrew M ^a   Johns, Terrance G ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 102; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INHIBITION; DRUG TARGETING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NEWBORN; NONHUMAN; ONCOGENE; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 65949106827     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09230     Document Type: Article

References (38)

1. Wen PY and Kesari S (2008). Malignant gliomas in adults. N Engl J Med 359, 492-507.
2. Cancer Genome Atlas Research Network (2008). Comprehensive genomic char- acterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
4. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, and Collins VP (1991). Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51, 2164-2172.
5. Frederick L, Wang XY, Eley G, and James CD (2000). Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387.
6. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, et al. (2003). A monoclonal antibody recog- nizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100,639-644.
7. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, and Schlessinger J (1985). Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147.
8. Pedersen MW, Meltorn M, Damstrup L, and Poulsen HS (2001). The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12, 745-760.
9. Sugawa N, Ekstrand AJ, James CD, and Collins VP (1990). Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87, 8602-8606.
10. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, and Bigner DD (1998). The class III variant of the epidermal growth factor receptor (EGFRvIII): character- ization and utilization as an immunotherapeutic target. J Neurovirol 4, 148-158.
11. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, and Vogelstein B (1987). Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84,6899-6903.
12. Schmidt MH, Furnari FB, Cavenee WK, and Bogler O (2003). Epidermal growth factor receptor signaling intensity determines intracellular protein interac- tions, ubiquitination, and internalization. Proc Natl Acad Sci USA 100,6505-6510.
13. Abounader R and Laterra J (2005). Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7, 436-451.
14. Benvenuti S and Comoglio PM (2007). The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213, 316-325.
15. Gentile A, Trusolino L, and Comoglio PM (2008). The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27,85-94.
16. Weinstein IB and Joe A (2008). Oncogene addiction. Cancer Res 68,3077-3080; discussion 3080.
17. Weinstein IB and Joe AK (2006). Mechanisms of disease: oncogene addiction- a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3, 448-457.
18. Sharma SV, Fischbach MA, Haber DA, and Settleman J (2006). "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12, 4392s-4395s.
19. Comoglio PM, Giordano S, and Trusolino L (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7, 504-516.
20. Gazdar AF, Shigematsu H, Herz J, and Minna JD (2004). Mutations and ad- diction to EGFR: the Achilles "heal" of lung cancers? Trends Mol Med 10,481-486.
21. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, et al. (2006). Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66, 1721-1729.
22. Rivera F, Vega-Villegas ME, Lopez-Brea MF, and Marquez R (2008). Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol 47,9-19.
23. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, and Lamszus K (2006). A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12, 6144-6152.
24. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, and White FM (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104, 12867-12872.
25. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, and Furnari FB (2007). The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13,1911-1925.
26. Comer JE, Chopra AK, Peterson JW, and Konig R (2005). Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun 73,8275-8281.
27. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, and Strom SC (2000). Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275,8806-8811.
28. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, et al. (2008). HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7,3499-3508.
29. Migliore C and Giordano S (2008). Molecular cancer therapy: can our expectation be MET? Eur J Cancer 44,641-651.
30. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, and Cavenee WK (2002). Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblasto- mas. Cancer Res 62,6764-6769.
31. Ziegler DS, Kung AL, and Kieran MW (2008). Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26, 493-500.
32. Habib AA, Hognason T, Ren J, Stefansson K, and Ratan RR (1998). The epi- dermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor beta receptor. J Biol Chem 273, 6885-6891.
33. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, and Malatesta P (2008). Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia 10,1373-1382; following 1382.
34. Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM, and Johns TG (2004). The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23,6095-6104.
35. Belda-Iniesta C, Carpeno Jde C, Saenz EC, Gutierrez M, Perona R, and Baron MG (2006). Long term responses with cetuximab therapy in glioblastoma multi- forme. Cancer Biol Ther 5,912-914.
36. Reardon DA. Phase II study of AMG 102, a fully human neutralizing anti- body against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. In: 2008 ASCO Annual Meeting; San Francisco, CA. Abstract no. 2051.
37. Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, and Lefranc F (2008). Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383-1392.
38. Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, et al. (2007). Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13,1253-1259.